Desmopressin as a hemostatic and blood sparing agent in bleeding disorders

Ajay Mohinani, Sarah Patel, Virginia Tan, Thomas Kartika, Sven Olson, Thomas G. DeLoughery, Joseph Shatzel

Research output: Contribution to journalReview articlepeer-review


Intranasal, subcutaneous, or intravenous desmopressin can be utilized to release von Willebrand Factor and Factor VIII into circulation, enhance platelet adhesion and shorten bleeding time. Due to these properties, desmopressin can be effective in controlling bleeding in mild hemophilia A, certain subtypes of von Willebrand disease and in acute bleeding from uremia, end stage renal disease, and liver disease. Its use, however, can be complicated by hyponatremia and rarely arterial thrombotic events. While desmopressin has also been used as a prophylactic blood sparing agent in orthopedic, renal, and hepatic procedures, clinical studies have shown limited benefit in these settings. The purpose of this article is to review the evidence for desmopressin in primary hematologic disorders, discuss its mechanism of action and evaluate its utility as a hemostatic and blood sparing product in various bleeding conditions.

Original languageEnglish (US)
JournalEuropean Journal of Haematology
StateAccepted/In press - 2023


  • bleeding
  • desmopressin
  • hemostasis
  • transfusion

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Desmopressin as a hemostatic and blood sparing agent in bleeding disorders'. Together they form a unique fingerprint.

Cite this